Economic evaluation in psychiatric pharmacogenomics: a systematic review
Kariofyllis Karamperis(University of Patras), Christina Mitropoulou(Golden Helix Foundation), George P. Patrinos(University of Patras), Panagiotis Papantoniou(University of Warwick), Konstantinos Mitropoulos(Hammersmith Hospital), Maria Koromina(Icahn School of Medicine at Mount Sinai), Filippos Kanellakis(University of Patras), Athanassios Vozikis(University of Piraeus), Daniel J. Müller(University of Toronto), Μαρία Σκώκου(University of Patras)
Cited by 59
Related Papers
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder
|The Canadian Journal of Psychiatry|2016|1.1k
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
|The Lancet|2023|508
Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severity
|Human Genomics|2020|213
Perfusion abnormalities in mild cognitive impairment and mild dementia in Alzheimer’s disease measured by pulsed arterial spin labeling MRI
|European Archives of Psychiatry and Clinical Neuroscience|2011|124